

# Patrizia Zentilin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6814668/publications.pdf>

Version: 2024-02-01

143  
papers

4,740  
citations

109321

35  
h-index

106344

65  
g-index

143  
all docs

143  
docs citations

143  
times ranked

2940  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastroesophageal Reflux and Pulmonary Fibrosis in Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 408-413.	5.6	251
2	The Role of Nonacid Reflux in NERD: Lessons Learned From Impedance-pH Monitoring in 150 Patients off Therapy. American Journal of Gastroenterology, 2008, 103, 2685-2693.	0.4	224
3	Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut, 2009, 58, 1185-1191.	12.1	206
4	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. European Respiratory Journal, 2013, 42, 1322-1331.	6.7	194
5	Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group. American Journal of Gastroenterology, 2005, 100, 2299-2306.	0.4	192
6	Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. American Journal of Gastroenterology, 2010, 105, 1053-1061.	0.4	190
7	NERD: an umbrella term including heterogeneous subpopulations. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 371-380.	17.8	184
8	Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 476-486.	3.7	172
9	Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. Journal of Gastroenterology, 2013, 48, 473-482.	5.1	157
10	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 542-547.	0.9	140
11	Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Digestive and Liver Disease, 2006, 38, 226-232.	0.9	139
12	Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointestinal Endoscopy, 1996, 44, 700-705.	1.0	135
13	Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 2018, 11, 1123-1134.	3.1	112
14	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. Journal of Gastroenterology, 2012, 47, 159-168.	5.1	102
15	Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD. Neurogastroenterology and Motility, 2015, 27, 1175-1182.	3.0	91
16	A 10-day levofloxacin-based therapy in patients with resistant infection: A controlled trial. Clinical Gastroenterology and Hepatology, 2004, 2, 997-1002.	4.4	80
17	Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux. Digestive and Liver Disease, 2004, 36, 565-569.	0.9	75
18	An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. Alimentary Pharmacology and Therapeutics, 2005, 21, 29-34.	3.7	74

#	ARTICLE	IF	CITATIONS
19	Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers. <i>Neurogastroenterology and Motility</i> , 2010, 22, 1061-e280.	3.0	72
20	Comparison of Isotope Ratio Mass Spectrometry and Nondispersive Isotope-Selective Infrared Spectroscopy for <sup>13</sup> C-Urea Breath Test. <i>American Journal of Gastroenterology</i> , 1999, 94, 1203-1208.	0.4	70
21	Eradication of <i>Helicobacter pylori</i> may reduce disease severity in rheumatoid arthritis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1291-1299.	3.7	62
22	Achalasia With Dense Eosinophilic Infiltrate Responds to Steroid Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 1104-1106.	4.4	62
23	Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment. <i>American Journal of Gastroenterology</i> , 2008, 103, 267-275.	0.4	60
24	Alginate controls heartburn in patients with erosive and nonerosive reflux disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 4371.	3.3	59
25	Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 81-88.	3.7	57
26	Gastric Aspiration versus Antimony and Glass pH Electrodes: A Simultaneous Comparative in Vivo Study. <i>Scandinavian Journal of Gastroenterology</i> , 1989, 24, 434-439.	1.5	52
27	Overweight is a risk factor for both erosive and non-erosive reflux disease. <i>Digestive and Liver Disease</i> , 2011, 43, 940-945.	0.9	52
28	Effect of gastric acid suppression on <sup>13</sup> C-urea breath test: comparison of ranitidine with omeprazole. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 291-297.	3.7	46
29	The appropriate use of proton-pump inhibitors. <i>Minerva Medica</i> , 2018, 109, 386-399.	0.9	46
30	Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 31-39.	2.8	42
31	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020, 12, 1422.	3.7	41
32	Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 893-898.	3.7	39
33	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1333-1343.	1.8	39
34	Variability in individual response to various doses of omeprazole. <i>Digestive Diseases and Sciences</i> , 1994, 39, 161-168.	2.3	38
35	Negative Effect of Ranitidine on The Results of Urea Breath Test for The Diagnosis of <i>Helicobacter Pylori</i> . <i>American Journal of Gastroenterology</i> , 2001, 96, 348-352.	0.4	36
36	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1554-1563.	4.4	34

#	ARTICLE	IF	CITATIONS
37	Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 1241-1247.	3.7	33
38	Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1733-1738.	3.7	32
39	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1074-1081.	3.7	32
40	A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1904-1909.	2.3	31
41	Updates in the field of non-esophageal gastroesophageal reflux disorder. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 827-838.	3.0	31
42	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13056.	3.4	30
43	Epidemiology and natural history of gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 175-183.	0.5	30
44	Lactulose Breath Test to Assess Oro-cecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 522-529.	3.4	29
45	Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012, 21, 157-63.	0.9	28
46	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. <i>Digestive and Liver Disease</i> , 2020, 52, 966-980.	0.9	27
47	<i>Helicobacter pylori</i> infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1057-1064.	3.7	26
48	Drugs for improving esophageal mucosa defense: where are we now and where are we going?. <i>Annals of Gastroenterology</i> , 2017, 30, 585-591.	0.6	26
49	Comparison of the Effects of Placebo, Ranitidine, Famotidine and Nizatidine on Intra-gastric Acidity by Means of Continuous pH Recording. <i>Digestion</i> , 1989, 42, 1-6.	2.3	25
50	Antimony and glass pH electrodes can be used interchangeably in 24-hour studies of gastric acidity. <i>Digestive Diseases and Sciences</i> , 1990, 35, 1473-1481.	2.3	25
51	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. <i>Annals of Hepatology</i> , 2018, 17, 830-835.	1.5	25
52	Latest insights into the hot question of proton pump inhibitor safety – a narrative review. <i>Digestive and Liver Disease</i> , 2020, 52, 842-852.	0.9	25
53	Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. <i>Digestive Diseases and Sciences</i> , 2003, 48, 315-321.	2.3	24
54	A safety review of proton pump inhibitors to treat acid-related digestive diseases. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 785-794.	2.4	24

#	ARTICLE	IF	CITATIONS
55	Clinical Relevance of Sampling Rate in the Characterization and Analysis of 24-Hour Gastric Acidity: A Report on 413 Cases. <i>Scandinavian Journal of Gastroenterology</i> , 1989, 24, 683-687.	1.5	22
56	Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. <i>Journal of Hepatology</i> , 1996, 25, 152-157.	3.7	21
57	Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 43-47.	3.7	21
58	Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity. <i>Toxicology and Applied Pharmacology</i> , 2016, 306, 113-119.	2.8	21
59	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 437-449.	3.1	21
60	Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1609-1621.	4.3	21
61	Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate <i>Helicobacter pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 643-649.	3.7	19
62	Cell proliferation of squamous epithelium in gastroesophageal reflux disease: correlations with clinical, endoscopic and morphological data. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 637-645.	3.7	19
63	Prevention Strategies for Esophageal Cancer—An Expert Review. <i>Cancers</i> , 2021, 13, 2183.	3.7	19
64	Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. <i>Digestive Diseases and Sciences</i> , 1998, 43, 459-463.	2.3	18
65	Time pattern of gastric acidity in Barrett's esophagus. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1379-1383.	2.3	17
66	No Evidence of an Association between <i>Helicobacter pylori</i> Infection and Raynaud Phenomenon. <i>Scandinavian Journal of Gastroenterology</i> , 2000, 35, 1251-1254.	1.5	17
67	Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD). <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 353-359.	3.7	17
68	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 278-295.	3.8	17
69	Comparable <i>Helicobacter pylori</i> eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. <i>Digestive and Liver Disease</i> , 2003, 35, 763-767.	0.9	16
70	Prognostic role of mean platelet volume in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 409-413.	0.9	16
71	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. <i>Digestive and Liver Disease</i> , 2020, 52, 1413-1420.	0.9	16
72	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. <i>Nutrients</i> , 2020, 12, 3363.	4.1	16

#	ARTICLE	IF	CITATIONS
73	&lt;p&gt;Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data&lt;/p&gt;. Clinical and Experimental Gastroenterology, 2020, Volume 13, 99-104.	2.3	14
74	Are Duodenal Ulcer Seasonal Fluctuations Paralleled by Seasonal Changes in 24-Hour Gastric Acidity and Helicobacter Pylori Infection?. Journal of Clinical Gastroenterology, 1996, 22, 178-181.	2.2	14
75	A Machine Learning Application to Predict Early Lung Involvement in Scleroderma: A Feasibility Evaluation. Diagnostics, 2021, 11, 1880.	2.6	14
76	Once and Twice Daily Doses of H2Antagonists Revisited, Using Continuous Intra-gastric pH Monitoring. Scandinavian Journal of Gastroenterology, 1988, 23, 385-390.	1.5	13
77	The effects of omeprazole 20 and 40 mg twice daily on intra-gastric acidity in duodenal ulcer patients.. Alimentary Pharmacology and Therapeutics, 1996, 10, 367-372.	3.7	13
78	Barrett's esophagus: proton pump inhibitors and chemoprevention II. Annals of the New York Academy of Sciences, 2011, 1232, 114-139.	3.8	12
79	Functional testing: pharyngeal pH monitoring and highâ€resolution manometry. Annals of the New York Academy of Sciences, 2013, 1300, 226-235.	3.8	12
80	Carditis in patients with gastro-oesophageal reflux disease: results of a controlled study based on both endoscopy and 24-h oesophageal pH monitoring. Alimentary Pharmacology and Therapeutics, 2004, 19, 1285-1292.	3.7	11
81	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Digestive and Liver Disease, 2020, 52, 862-868.	0.9	11
82	Circadian Acidity Pattern in Prepyloric Ulcers: A Comparison with Normal Subjects and Duodenal Ulcer Patients. Scandinavian Journal of Gastroenterology, 1993, 28, 772-776.	1.5	10
83	Advancements in the use of manometry and impedance testing for esophageal functional disorders. Expert Review of Gastroenterology and Hepatology, 2019, 13, 425-435.	3.0	10
84	Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer. Digestive Diseases and Sciences, 1989, 34, 1043-1046.	2.3	9
85	The Role of Acid in Functional Dyspepsia. American Journal of Gastroenterology, 2011, 106, 1168.	0.4	9
86	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. Annals of the New York Academy of Sciences, 2013, 1300, 166-186.	3.8	9
87	Twentyâ€fourâ€Hour Control of Gastric Acidity by Twiceâ€Daily Doses of Placebo, Nizatidine 150 mg, Nizatidine 300 mg, and Ranitidine 300 mg. Journal of Clinical Pharmacology, 1993, 33, 70-74.	2.0	8
88	Single Morning and Nightly Doses of Ranitidine 300 mg: An Appraisal of Their Antisecretory Effects by Continuous pH Monitoring. Digestion, 1991, 48, 141-148.	2.3	7
89	Effect of Helicobacter pylori eradication on 24-hour gastric pH and duodenal gastric metaplasia. Digestive Diseases and Sciences, 2000, 45, 1315-1321.	2.3	7
90	The contribution of intraepithelial inflammatory cells to the histological diagnosis of microscopic esophagitis. Esophagus, 2016, 13, 80-87.	1.9	7

#	ARTICLE	IF	CITATIONS
91	Ulcer healing: Does omeprazole efficacy depend on daytime or 24-hour acid inhibition?. <i>Gastroenterology</i> , 1990, 99, 1858-1860.	1.3	6
92	Ulcer heterogeneity: Further arguments for a range of antisecretory treatment. <i>Digestive Diseases and Sciences</i> , 1990, 35, 921-923.	2.3	6
93	Duration of Acid Suppression in H <sub>2</sub> -Antagonist Nonresponders. <i>Digestion</i> , 1992, 51, 185-192.	2.3	6
94	Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 11-28.	3.8	6
95	Light microscopy is useful to better define NERD and functional heartburn. <i>Gut</i> , 2014, 63, 368-368.	12.1	6
96	Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1473-1482.	2.3	5
97	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 569-574.	3.4	5
98	Correlation Between Skin and Affected Organs in 52 Sclerodermic Patients Followed in a Diseases Management Team: Development of a Risk Prediction Model of Organ-Specific Complications. <i>Frontiers in Immunology</i> , 2021, 12, 588753.	4.8	5
99	A comparison of the effects on intragastric acidity of bedtime or dinnertime administration of a once daily dose of famotidine. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 203-207.	1.9	4
100	Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor. <i>Digestive and Liver Disease</i> , 2005, 37, 454-457.	0.9	4
101	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, , 1-10.	3.0	4
102	A Pharmacodynamic Study of Two Omeprazole Regimens Suitable for Long-Term Treatment of Duodenal Ulcer. <i>Scandinavian Journal of Gastroenterology</i> , 1994, 29, 488-492.	1.5	3
103	Esophageal biopsies in the management of GERD: complementary tool for many but not for all. <i>Human Pathology</i> , 2014, 45, 2512-2513.	2.0	3
104	Circadian gastric acidity and <i>Helicobacter pylori</i> infection in patients with chronic pancreatitis. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1079-1083.	2.3	2
105	<i>Helicobacter pylori</i> and tolerance to H <sub>2</sub> -blockers. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 289-290.	3.7	2
106	The Relevance of Weakly Acidic Reflux in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, e21-e22.	1.3	2
107	Nonerosive reflux disease and functional heartburn are clearly separate entities. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 749-750.	1.6	2
108	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 129-130.	2.4	2

#	ARTICLE	IF	CITATIONS
109	Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure. <i>World Journal of Gastroenterology</i> , 2009, 15, 5700.	3.3	2
110	Mealtime versus nighttime acid inhibition. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1368-1372.	2.3	1
111	S1065 Correlation Between Pulmonary Fibrosis and GERD in Scleroderma (SSc) Patients: Studies Using 24-Hour Ambulatory Intraluminal pH-Impedance (MII-pH). <i>Gastroenterology</i> , 2008, 134, A-169-A-170.	1.3	1
112	Nocturnal reflux and sleep disturbances: An overlooked link in the past. <i>Digestive and Liver Disease</i> , 2011, 43, 755-756.	0.9	1
113	The reason for failure of on-demand PPI therapy in NERD patients. <i>Neurogastroenterology and Motility</i> , 2011, 23, 811-811.	3.0	1
114	The relevance of symptom association analysis in GORD patients undergoing anti-reflux surgery. <i>Gut</i> , 2012, 61, 326.1-326.	12.1	1
115	It is time to plan clinical trials on true NERD patients. <i>Neurogastroenterology and Motility</i> , 2012, 24, 885-886.	3.0	1
116	Esophageal acid exposure still plays a major role in patients with NERD. <i>Journal of Gastroenterology</i> , 2013, 48, 552-553.	5.1	1
117	Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 318-319.	2.4	1
118	P.06.2 PROTON PUMP INHIBITOR THERAPY IMPROVES ESOPHAGEAL SYMPTOMS BY RESTORING A NORMAL ESOPHAGEAL PERISTALSIS IN PPI-REE. <i>Digestive and Liver Disease</i> , 2018, 50, e179.	0.9	1
119	P.06.5 Eesomeprazole, Rabeprazole and Pantoprazole are Equally Effective in Inducing Endoscopic and Histologic Remission in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Digestive and Liver Disease</i> , 2018, 50, e180-e181.	0.9	1
120	The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1011-1012.	3.1	1
121	Letter: predictive factors for treatment discontinuation in IBD – anti-TNF trough levels and anti-drug antibodies. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 536-537.	3.7	1
122	Complexity and diversity of gastroesophageal reflux disease phenotypes. <i>Minerva Gastroenterology</i> , 2017, 63, 198-204.	0.5	1
123	Author reply to Letter to the Editor: 'Functional heartburn': symptom for achalasia or hypertensive lower oesophageal sphincter? - Riegler et al.. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 97-98.	3.7	0
124	Comment to – Current applications of evolving methodologies in gastroesophageal reflux disease testing –. <i>Digestive and Liver Disease</i> , 2011, 43, 835.	0.9	0
125	The Relevance of Reflux Monitoring Off Therapy. <i>American Journal of Gastroenterology</i> , 2011, 106, 1558-1559.	0.4	0
126	Studies on factors predicting GORD response to proton-pump inhibitors: NERD subpopulations need to be analysed separately. <i>Gut</i> , 2012, 61, 1368.2-1369.	12.1	0



#	ARTICLE	IF	CITATIONS
127	Symptom association analysis is important in GERD patients undergoing endoscopic therapy. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 832.	1.0	0
128	Non-Erosive Reflux Disease is More Complex Than Negative Endoscopy Only. <i>American Journal of Gastroenterology</i> , 2013, 108, 1657-1658.	0.4	0
129	Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 710-711.	2.4	0
130	Su1101 Esophago-Gastric Junction Morphology Variability During Standard Manometric Protocol and After Esophageal Stimulation and Body Change Position. <i>Gastroenterology</i> , 2016, 150, S470.	1.3	0
131	Sa1268 Feasibility of High Resolution Impedance Manometry in Assessing Barrett's Esophagus Extension. <i>Gastroenterology</i> , 2016, 150, S263-S264.	1.3	0
132	Proximal Esophageal Baseline Impedance Levels are Able to Discriminate between Scleroderma Patients with and without Esophageal Involvement. <i>Gastroenterology</i> , 2017, 152, S654.	1.3	0
133	Response to Optimal PPI Therapy, Association with Atypical and Functional GI Symptoms in NERD Patients: Results from Nerone Study. <i>Gastroenterology</i> , 2017, 152, S3-S4.	1.3	0
134	Different Proton Pump Inhibitors are Equally Effective in Inducing Endoscopic and Histologic Remission in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860-S861.	1.3	0
135	Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860.	1.3	0
136	Sa1132 - Faecal Calprotectin as a Biomarker of Intestinal Inflammation is not a Useful Tool for the Diagnosis and Managemnt of Patients with Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2018, 154, S-252.	1.3	0
137	Su1067 - Clinical and Impedance-Ph Factors Associated to PPI Response in Patients with with Extraesophageal Symptoms Suggestive of Gerd. <i>Gastroenterology</i> , 2018, 154, S-474-S-475.	1.3	0
138	Mo1142 "Achalasia is a Common Finding in Patients with Eoe Undergoing High Resolution Manometry. <i>Gastroenterology</i> , 2019, 156, S-720-S-721.	1.3	0
139	Mo1143 "Esophageal Motility Disorders in Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2019, 156, S-721.	1.3	0
140	Mo1141 "Fecal Eosinophil Cationic Protein As Potential Marker of Disease Activity in Patients with Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2019, 156, S-720.	1.3	0
141	Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. <i>Digestive and Liver Disease</i> , 2020, 52, 792-793.	0.9	0
142	Liver Stiffness Improvement Is Associated With Amelioration of Indirect Parameters of Portal Hypertension One Year After Sustained Virological Response to Direct Acting Antivirals in Chronic Hepatitis C Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, S577.	0.4	0
143	Pharmacotherapies in eosinophilic esophagitis: state of the art. <i>Minerva Gastroenterology</i> , 2022, 68, 69-76.	0.5	0